Cargando…
Reduced occipital GABA in Parkinson disease with visual hallucinations
OBJECTIVE: To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex. METHODS: We utilized magnetic resonance spectroscopy to investigate occipital GABA levels in 36 participants with PD, 19 with and...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105043/ https://www.ncbi.nlm.nih.gov/pubmed/30021920 http://dx.doi.org/10.1212/WNL.0000000000006007 |
_version_ | 1783349596604334080 |
---|---|
author | Firbank, Michael J. Parikh, Jehill Murphy, Nicholas Killen, Alison Allan, Charlotte L. Collerton, Daniel Blamire, Andrew M. Taylor, John-Paul |
author_facet | Firbank, Michael J. Parikh, Jehill Murphy, Nicholas Killen, Alison Allan, Charlotte L. Collerton, Daniel Blamire, Andrew M. Taylor, John-Paul |
author_sort | Firbank, Michael J. |
collection | PubMed |
description | OBJECTIVE: To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex. METHODS: We utilized magnetic resonance spectroscopy to investigate occipital GABA levels in 36 participants with PD, 19 with and 17 without complex visual hallucinations, together with 20 healthy controls without hallucinations. In addition, we acquired T1-weighted MRI, whole-brain fMRI during a visual task, and diffusion tensor imaging. RESULTS: We found lower GABA+/creatine in PD with visual hallucinations (0.091 ± 0.010) vs those without (0.101 ± 0.010) and controls (0.099 ± 0.010) (F(2,49) = 4.5; p = 0.016). Reduced gray matter in the hallucinations group was also observed in the anterior temporal lobe. Although there were widespread reductions in white matter integrity in the visual hallucinations group, this was no longer significant after controlling for cognitive function. CONCLUSIONS: The data suggest that reduced levels of GABA are associated with visual hallucinations in PD and implicate changes to the ventral visual stream in the genesis of visual hallucinations. Modulation of visual cortical excitability through, for example, pharmacologic intervention, may be a promising treatment avenue to explore. |
format | Online Article Text |
id | pubmed-6105043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-61050432018-08-23 Reduced occipital GABA in Parkinson disease with visual hallucinations Firbank, Michael J. Parikh, Jehill Murphy, Nicholas Killen, Alison Allan, Charlotte L. Collerton, Daniel Blamire, Andrew M. Taylor, John-Paul Neurology Article OBJECTIVE: To investigate the relationship between visual hallucinations in Parkinson disease (PD) and levels of γ-aminobutyric acid (GABA) in the primary visual cortex. METHODS: We utilized magnetic resonance spectroscopy to investigate occipital GABA levels in 36 participants with PD, 19 with and 17 without complex visual hallucinations, together with 20 healthy controls without hallucinations. In addition, we acquired T1-weighted MRI, whole-brain fMRI during a visual task, and diffusion tensor imaging. RESULTS: We found lower GABA+/creatine in PD with visual hallucinations (0.091 ± 0.010) vs those without (0.101 ± 0.010) and controls (0.099 ± 0.010) (F(2,49) = 4.5; p = 0.016). Reduced gray matter in the hallucinations group was also observed in the anterior temporal lobe. Although there were widespread reductions in white matter integrity in the visual hallucinations group, this was no longer significant after controlling for cognitive function. CONCLUSIONS: The data suggest that reduced levels of GABA are associated with visual hallucinations in PD and implicate changes to the ventral visual stream in the genesis of visual hallucinations. Modulation of visual cortical excitability through, for example, pharmacologic intervention, may be a promising treatment avenue to explore. Lippincott Williams & Wilkins 2018-08-14 /pmc/articles/PMC6105043/ /pubmed/30021920 http://dx.doi.org/10.1212/WNL.0000000000006007 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Firbank, Michael J. Parikh, Jehill Murphy, Nicholas Killen, Alison Allan, Charlotte L. Collerton, Daniel Blamire, Andrew M. Taylor, John-Paul Reduced occipital GABA in Parkinson disease with visual hallucinations |
title | Reduced occipital GABA in Parkinson disease with visual hallucinations |
title_full | Reduced occipital GABA in Parkinson disease with visual hallucinations |
title_fullStr | Reduced occipital GABA in Parkinson disease with visual hallucinations |
title_full_unstemmed | Reduced occipital GABA in Parkinson disease with visual hallucinations |
title_short | Reduced occipital GABA in Parkinson disease with visual hallucinations |
title_sort | reduced occipital gaba in parkinson disease with visual hallucinations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105043/ https://www.ncbi.nlm.nih.gov/pubmed/30021920 http://dx.doi.org/10.1212/WNL.0000000000006007 |
work_keys_str_mv | AT firbankmichaelj reducedoccipitalgabainparkinsondiseasewithvisualhallucinations AT parikhjehill reducedoccipitalgabainparkinsondiseasewithvisualhallucinations AT murphynicholas reducedoccipitalgabainparkinsondiseasewithvisualhallucinations AT killenalison reducedoccipitalgabainparkinsondiseasewithvisualhallucinations AT allancharlottel reducedoccipitalgabainparkinsondiseasewithvisualhallucinations AT collertondaniel reducedoccipitalgabainparkinsondiseasewithvisualhallucinations AT blamireandrewm reducedoccipitalgabainparkinsondiseasewithvisualhallucinations AT taylorjohnpaul reducedoccipitalgabainparkinsondiseasewithvisualhallucinations |